Executive Team

Michel Goldman’s scientific achievements resulted in an ISI Highly Cited Scientist nomination in 2006 by the Thomson Institute for Scientific Information. In 1992, Michel Goldman received the Medical Prize Lucien Steinberg (shared with Pr. Peter Piot) and in 2000 the Quinquiennal Prize of the Belgian National Fund for Scientific Research for Clinical Sciences. He held the Francqui Chair at the University of Namur in 1999, at the University of Liège in 2003, and the Spinoza chair at the University of Amsterdam, the Netherlands in 2001. In 2007, Michel Goldman was awarded the degree of Doctor Honoris Causa of the University of Lille, France.

Between 1998 and 2011, he was part-time Visiting Professor at MIT and Research Director of CEPR. Laureate of the 1998 Francqui Prize and of the 2003 Yrjo Jahnsson Prize for Economics, he was a founding member of the Scientific Council of the European Research Council (2007-2012). He is a member of the Académie Royale De Belgique and Foreign Honorary Member of the American Academy of Arts and Science. He is also Honorary Vice-Governor of the National Bank of Belgium, where he served between 2011 and 2017.
He has widely published in the areas of contract theory, organization economics, innovation, and banking and finance. Between April 2020 and March 2022, he was involved in expert groups advising the Belgian authorities on its covid management strategy. In 2023, he was elected Foreign Honorary Member of the American Economic Association.

Hilde has been Academic Coordinator, Treasurer and Vice-chair in ENP Belgium (2016-2020), the Belgian Patient Platform, supported by EUPATI (European Patients’ Academy on Therapeutic Innovation). There she laid the foundation for her work on patient-centricity.
She holds a Master Degree in Biomedical Science (Ghent University, Belgium), a Master Degree in General Management (Vlerick Business School, Belgium), Master Degree in Intellectual Property (IP) Law (Brussels University, Belgium) and a PhD in Biomedical Sciences from the University of Leuven (Belgium). Hilde worked as a science consultant (Altran) and was a patent engineer for several years (BiIP).

His research focuses mainly on political economics and economic policy, one application of the latter being competition in the pharmaceutical market. He also worked on economic reforms (tax, pensions, institution building). Previously, he acted as an economic expert for a multinational enterprise, for the OECD, and for the World Bank. He sits on the scientific board of the National Bank of Belgium and of the Belgian Price Observatory.

Graduating in medicine from the Université Libre de Bruxelles (ULB) in 1996, Olivier pursued a Master’s degree in Clinical Biology in 2001, followed by a PhD in Biomedical Sciences in 2006. In 2008, he was appointed Head of the Department of Clinical Biology at the network of public university hospitals in Brussels. In 2016, he joined the Division of Infection and Immunity at University College London (UCL) as an Honorary Lecturer. In 2017, he established the Research and Technological Innovation Unit (UNRIT) of the Brussels University Hospital Laboratory (LHUB-ULB), a cross-disciplinary platform aimed at fostering clinical and translational research within Brussels’ university hospitals.
Currently, Olivier is a Professor of Environmental Health at the School of Public Health (ESP) and the Faculty of Medicine at ULB. His research focuses primarily on emerging pathogens and combating antibiotic resistance. Since 2000, he has overseen the consolidation of several microbiology laboratories, enabling the establishment of infectious disease surveillance programs in both industrialized and low- to middle-income countries.
His collaboration with industry in developing new approaches to diagnosing and controlling infectious diseases is particularly noteworthy. His expertise has led him to become a member of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) and the Coordinating Committee for Food- and Waterborne Disease Surveillance Networks of the ECDC since 2014.
With over 200 scientific publications and significant contributions to several book chapters, Olivier is also a member of numerous scientific societies, including the European Society of Clinical Microbiology and Infectious Diseases and the American Society for Microbiology.

Olivier is also academic director for Solvay Entrepreneurs and StartLAB.Brussels.
Beside his activities for the business school, Olivier is an active Board member or strategic advisor in a set of growth-oriented entrepreneurial ventures.
Over the last 25 years, Olivier has coached 150+ new and growing firms, published multiple papers on entrepreneurship, entrepreneurial finance and strategy in entrepreneurial ventures.
Before joining the U.L.B., Olivier has been part of the entrepreneurial team of OpenHR (2000-2006), a successful Belgian IT venture company specialized in HR management software, where he was CFO. Olivier has also been the Managing Director of EEBIC, an incubator in Brussels (1995-1999) and Adviser to the Minister of Economy of the Brussels Region (1991-1994).
Olivier holds a Master’s degree in Business Engineering (ULB, 1991) and a PhD in Entrepreneurship (ULB, 2008).
Main interests: Entrepreneurship, Startups and scale-ups strategies, Effectuation, Lean Launchpad, Design Thinking, Entrepreneurial Finance (incl. Venture Capital / Private Equity), Coaching, High-tech Entrepreneurship, Corporate Entrepreneurship, Innovation Policy.
Operational Team


Caroline holds a Master’s degree in International Management with a specialization in Economics of Developing Countries from Ichec Brussels Management School. She is currently enrolled in an second Master’s degree in Population and Development Sciences at ULB.
Post-Docs


PhD students

Marie holds a MSc degree in bioengineering with a specialization in Science, Technology and Quality of Food (UCL, Belgium), a Postgraduate degree in Management (ICHEC Business Management School, Belgium) and a certificate in Clinical Studies (Cefochim, Belgium).

She is a research fellow at the Institute for Interdisciplinary Innovation in healthcare where she is achieving a Ph.D. in Biomedical Sciences.
She works as an assistant at the Faculty of Medicine of the Université Libre de Bruxelles. Prior to this, she was a science teacher at the College Saint Pierre.
Her research focuses on health economics and cognitive neurosciences in the field of rare diseases.

Prior to her position at I3h, she was a research and teaching assistant at the Centre for Global Health at Trinity College and worked as an analyst for a small consultancy firm in Israel, conducting research for med-tech startups and assisting them in securing innovation and knowledge transfer grants from local and international governmental sources. Previously, she was a clinical research assistant and coordinator for 3 years at the Sagol Brain Institute at Tel Aviv Medical Center. Her current research explores the relationship between innovation policies, alternative IP models and global diffusion and affordability of new and existing health technologies.

Prior to joining I3h, Atul worked as a Program Associate with the global health NGO – PATH, in program planning and implementation of Covid-19 and Digital Health projects in India. He also has research experience in digital health and health promotion through eHealth projects with Nanyang Technological University, Singapore, working on projects in designing healthcare apps and work experience in market research in oncology and antibiotic markets. He has been involved with voluntary health organizations in Tanzania and Nepal in telemedicine and health systems strengthening.
With research interests in access to medicines and healthcare program implementation, Atul’s present research focuses on collaborative models in healthcare to improve access to vaccines in Low-and-Middle Income Countries, particularly in Malaria and Neglected Tropical Diseases.

His research interest lies in the intersection of health economics and industrial organization. He is currently involved in the Hi-Prix project (Health innovation next generation pricing models: Balancing sustainability of innovation with sustainability of health care). His current research focuses on policy analysis on orphan regulation in the EU, orphan drugs’ market and innovation in pharmaceutical industry, e.g., the role of academia, biotech and big pharma companies in the whole development process of medicine.

Additionally, Sam is Portfolio Director at Waterland Private Equity where he supports companies in defining and executing their strategy. He holds a Master of Engineering degree from KULeuven, Belgium.

He started his research in 2018 and focuses on the “Development of an interdisciplinary model of prescription management in the elderly”. His work is based on field practice, with a predominant use of qualitative studies. The research topics are: improving the quality of prescribing in the elderly, interdisciplinary collaboration around their medication and defining the roles of health care providers in this context.
He also has a Interuniversity Certificate in sports medicine and physiotherapy (ULG/UCL).
His current activities combine general practice and sports medicine, medical research and family planning consulting.